12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aflunov regulatory update

In November, the European Commission approved Aflunov vaccine from Novartis to prevent influenza A (H5N1) virus infection in adults....

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >